SEC Form 4 · accession 0001209191-18-050473
Biohaven Pharmaceutical Holding Co Ltd. · BHVN
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Robert Repella
Director
Period of report
Sep 7, 2018
Accepted (ET)
Sep 11, 2018 · 4:19 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001689813
Table I — non-derivative securities
No Table I lines on this filing.
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (right to buy)F1 | $35.50 | Sep 7, 2018 | A | 36,000 | A | — | Sep 6, 2028 | Common Shares | 36,000 | 36,000 | D |
Explanation of responses
- F1This option grant was made pursuant to the issuer's non-employee director compensation policy. The common shares underlying this option vest in three equal installments on September 7, 2019, 2020 and 2021, subject to the reporting person's continuous service with the issuer at each vesting date.